June 2026 Research Update

This month added a clearer signal that some immune-targeting medicines may help when Evans syndrome is difficult to control, with the strongest new evidence coming from an adult sirolimus trial. In that study, many people improved within a few months and responses often lasted through a year, and side effects were commonly described as mild and reversible. A separate single-patient report described improvement using efgartigimod as a way to reduce steroid exposure, but a case report cannot tell how often this works for others. [1] [2]

In the sirolimus study, adults with relapsed or refractory warm autoimmune hemolytic anemia or Evans syndrome had an overall response rate of 80.0% for Evans syndrome at 6 months, with a complete response rate of 46.7%. The study also reported that responses were often maintained at 12 months, and treatment-emergent side effects were reported in 28.2% of participants. For patients, this helps put sirolimus on the map as a medicine being formally tested for longer-term control and for reducing reliance on steroids, though the study was open-label and from a single center. [1]

In a single older adult with Evans syndrome and a long history of immune thrombocytopenia, efgartigimod was followed by higher platelet counts, more stable hemolysis, and successful tapering of corticosteroids without relapse in the report. This adds an early, real-world example that this antibody-based treatment (designed to lower harmful IgG antibodies) might be a steroid-sparing option for some people with IgG-driven disease, but it remains uncertain how generalizable this is from one person. [2]

For patients and caregivers, these studies mainly add to the research picture rather than changing anything immediately. The sirolimus trial provides medium-strength evidence that a non-steroid immune-suppressing approach can produce sustained improvements in blood counts for many adults with hard-to-control disease, with side effects reported but often described as manageable. The efgartigimod report is much earlier evidence (one person), but it helps clarify what a successful steroid-sparing course can look like and supports further study. What remains uncertain is how these options compare to other approaches and which patient subgroups are most likely to benefit. [1] [2]

This month strengthened the idea that Evans syndrome often sits within a broader immune landscape, especially in children, where the question is not only treating low blood counts but also understanding what else may develop over time. One pediatric cohort found that persistent antinuclear antibody (ANA) positivity separated a higher-risk group that later developed systemic lupus erythematosus (lupus), while ANA-negative children did not develop lupus in that dataset. Another pediatric center review showed that Evans syndrome can be one of several less-common explanations for transfusion-dependent anemia, alongside bone marrow failure and inherited blood disorders. [3] [4]

In the pediatric autoimmune cytopenias cohort, 6 of 35 ANA-positive children developed lupus, with a median time of 2.5 years, while none of the ANA-negative children did. The main message for families is that a positive ANA over time may help identify a subgroup that needs closer long-term attention for lupus-type symptoms and labs, although this was a single-center retrospective study and follow-up did not extend into adulthood. It also remains unclear from this report how often ANA-positive children who never develop lupus will still have ongoing cytopenias or other immune issues. [3]

In the pediatric transfusion-dependent anemia review, most children had hemoglobin disorders, but 13 of 93 had other causes, including immune-mediated disorders such as Evans syndrome. Many of these non-hemoglobinopathy cases had enlarged liver and spleen (8 of 13), and the authors emphasized a structured workup to avoid missing treatable immune or systemic causes. For patients, this supports the idea that transfusion dependence is a sign that deserves a careful search for the underlying reason, because Evans syndrome may be one piece of a larger diagnostic puzzle. [4]

For families, these studies matter most for understanding prognosis and the possible need for long-term follow-up rather than pointing to a new treatment. Persistent ANA positivity in children with autoimmune cytopenias may flag a higher chance of later lupus in some patients, which can help explain why clinicians sometimes repeat autoimmune testing over time. The transfusion-dependent anemia review helps clarify that Evans syndrome can be mistaken for other causes of chronic anemia unless the evaluation is broad. Uncertainties include how these findings apply outside the specific centers studied and what the long-term outcomes are as children reach adulthood. [3] [4]

This month, case reports highlighted how Evans syndrome can appear in medically complex situations, including after immune checkpoint inhibitor cancer therapy and alongside other autoimmune diseases. Across these reports, a recurring picture is that Evans syndrome may be triggered or unmasked when the immune system is strongly stimulated (such as with PD-1 or PD-L1 inhibitors), and that management often involves steroids and other immune-suppressing treatments, sometimes with escalation when relapses occur. Other reports focused on uncommon but high-impact complications related to very low platelets, where urgent hospital care and coordination across specialties mattered. Because these are individual cases, they show what can happen, not how often it happens. [5] [6] [7] [8] [9]

Two men with advanced cholangiocarcinoma developed Evans syndrome during durvalumab maintenance therapy, with onset reported after 11 months, and both recovered their blood counts with corticosteroids. A separate case described recurrent mixed autoimmune hemolytic anemia with thrombocytopenia after exposure to a PD-1 inhibitor (retifanlimab), where steroids and IVIG were not enough to prevent relapses and prolonged rituximab was used to reach more sustained hemoglobin stability. For patients, these reports make the immune trigger more concrete: treatments that "take the brakes off" the immune system for cancer can also, in rare cases, lead to immune attacks on blood cells. [5] [6]

One case described Evans syndrome occurring together with ANCA-associated vasculitis (most consistent with microscopic polyangiitis), presenting with progressive strokes and kidney involvement, and the report described partial blood and kidney improvement after plasma exchange and cyclophosphamide while thrombocytopenia persisted. Another case described a spontaneous spinal epidural hematoma in a person with Evans syndrome, where urgent surgery plus platelet support and immune treatment was followed by preserved neurologic function at follow-up. These cases underline that Evans syndrome can overlap with other autoimmune inflammation or, when platelets are very low, contribute to rare bleeding events that require urgent evaluation. [7] [8]

An additional case in an older man with long-standing immune thrombocytopenia described development of warm autoimmune hemolytic anemia requiring transfusions and high-dose corticosteroids, complicated by new atrial flutter and decisions about balancing clot prevention with bleeding risk. For caregivers, this illustrates a real-world issue in Evans syndrome: treatment choices and supportive care can become tightly linked to other health conditions, especially in older adults. It also reinforces why some patients experience periods of stabilization followed by flare-ups that lead to hospital-based care. [9]

For patients and caregivers, these reports mainly help explain the range of situations in which Evans syndrome can show up and why care sometimes becomes complex. The checkpoint inhibitor cases make it clearer that Evans syndrome can begin even many months after starting immune-based cancer therapy, and that steroids may lead to recovery in some reported patients. The bleeding, neurologic, and heart-rhythm cases show that complications can sometimes drive urgent decisions and multi-specialty care, but they do not tell how likely these events are for any given person. What remains uncertain is which risk factors predict these complications or relapses, since case reports cannot answer frequency questions. [5] [6] [7] [8] [9]